E Xhepa1, T Tada1, S Cassese1, L King1, I Ott1, M Fusaro1, A Kastrati2, R A Byrne1. 1. Deutsches Herzzentrum, Technische Universität, Lazarettstrasse 36, 80636 Munich, Germany. 2. Deutsches Herzzentrum, Technische Universität, Lazarettstrasse 36, 80636 Munich, Germany. Electronic address: kastrati@dhm.mhn.de.
Abstract
AIMS: The use of biodegradable-polymer drug-eluting stents has been shown to provide favorable results when compared with durable polymer drug-eluting stents and long-term follow up data have recently shown significant reductions in terms of very late stent thrombosis. Aim of the present study was to assess the safety and efficacy profile of a novel biodegradable polymer DES, the Yukon Choice Flex sirolimus-eluting stent. METHODS: We report here the one-year clinical outcomes associated with the use of the Yukon Choice Flex sirolimus-eluting stent in an all-comers patient population. The present stent represents a further refinement of the stent platform tested in the ISAR TEST 3 and 4 randomized clinical trials. A total of 778 consecutive patients undergoing implantation of this stent were enrolled in the present observational study and prospectively followed for one year. RESULTS: The use of the Yukon Choice Flex stent in a patient population with complex coronary lesion morphology was associated with optimal immediate angiographic results. At one year follow up the rates of death, myocardial infarction, definite stent thrombosis and ischemia-driven target lesion revascularization were respectively 2.4%, 1.9%, 0.3% and 11.3%. CONCLUSIONS: The use of the sirolimus-eluting biodegradable polymer Yukon Choice Flex stent in an all-comers population of patients with complex coronary artery disease is associated with a favorable safety and efficacy profile up to one year follow up.
RCT Entities:
AIMS: The use of biodegradable-polymer drug-eluting stents has been shown to provide favorable results when compared with durable polymer drug-eluting stents and long-term follow up data have recently shown significant reductions in terms of very late stent thrombosis. Aim of the present study was to assess the safety and efficacy profile of a novel biodegradable polymer DES, the Yukon Choice Flex sirolimus-eluting stent. METHODS: We report here the one-year clinical outcomes associated with the use of the Yukon Choice Flex sirolimus-eluting stent in an all-comers patient population. The present stent represents a further refinement of the stent platform tested in the ISAR TEST 3 and 4 randomized clinical trials. A total of 778 consecutive patients undergoing implantation of this stent were enrolled in the present observational study and prospectively followed for one year. RESULTS: The use of the Yukon Choice Flex stent in a patient population with complex coronary lesion morphology was associated with optimal immediate angiographic results. At one year follow up the rates of death, myocardial infarction, definite stent thrombosis and ischemia-driven target lesion revascularization were respectively 2.4%, 1.9%, 0.3% and 11.3%. CONCLUSIONS: The use of the sirolimus-eluting biodegradable polymer Yukon Choice Flex stent in an all-comers population of patients with complex coronary artery disease is associated with a favorable safety and efficacy profile up to one year follow up.
Authors: Michael Joner; Aloke V Finn; Andrew Farb; Erik K Mont; Frank D Kolodgie; Elena Ladich; Robert Kutys; Kristi Skorija; Herman K Gold; Renu Virmani Journal: J Am Coll Cardiol Date: 2006-05-05 Impact factor: 24.094
Authors: Christian Spaulding; Joost Daemen; Eric Boersma; Donald E Cutlip; Patrick W Serruys Journal: N Engl J Med Date: 2007-02-12 Impact factor: 91.245
Authors: Adnan Kastrati; Julinda Mehilli; Jürgen Pache; Christoph Kaiser; Marco Valgimigli; Henning Kelbaek; Maurizio Menichelli; Manel Sabaté; Maarten J Suttorp; Dietrich Baumgart; Melchior Seyfarth; Matthias E Pfisterer; Albert Schömig Journal: N Engl J Med Date: 2007-02-12 Impact factor: 91.245
Authors: Htut K Win; Angel E Caldera; Kelly Maresh; John Lopez; Charanjit S Rihal; Manish A Parikh; Juan F Granada; Sachin Marulkar; Deborah Nassif; David J Cohen; Neal S Kleiman Journal: JAMA Date: 2007-05-09 Impact factor: 56.272
Authors: Patrick W Serruys; Vasim Farooq; Bindu Kalesan; Ton de Vries; Pawel Buszman; Axel Linke; Thomas Ischinger; Volker Klauss; Franz Eberli; William Wijns; Marie Claude Morice; Carlo Di Mario; Roberto Corti; Diethmar Antoni; Hae Y Sohn; Pedro Eerdmans; Tessa Rademaker-Havinga; Gerrit-Anne van Es; Bernhard Meier; Peter Jüni; Stephan Windecker Journal: JACC Cardiovasc Interv Date: 2013-08 Impact factor: 11.195
Authors: Aloke V Finn; Gaku Nakazawa; Michael Joner; Frank D Kolodgie; Erik K Mont; Herman K Gold; Renu Virmani Journal: Arterioscler Thromb Vasc Biol Date: 2007-05-17 Impact factor: 8.311